Brief: Coloplast Revised Guidance For FY 2024/25
May 1 (Reuters) - Coloplast A/S COLOb.CO: OUTLOOK FY ORGANIC GROWTH 7% FY 2024/2025: EBIT MARGIN BEFORE SPECIAL ITEMS IS NOW EXPECTED TO BE 27-28%, FROM PREVIOUSLY AROUND 28% Source text: ID:nGNE6K0jTp Further company coverage: [COLOb.CO] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Coloplast A/S
See all newsMorgan Stanley sees selective medtech opportunities on growth recovery
Brief: Coloplast’s Inflatable Penile Prosthesis Approved By FDA
Denmark's Coloplast Q2 organic revenue rises 6% on urology momentum
Brief: Coloplast Books DKK 3 Bln Impairment In H1
Brief: Coloplast Receives Innovative Technology Contract From Vizient For Biatain® Silicone Fit